INAB

In8Bio, Inc.

• TipRanks·3h ago

  IN8bio: Buy Rating Reiterated with $5 Price Target Unchanged on Promising Oncology Pipeline

• Dow Jones·10/06 20:00

  Press Release: IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

• NASDAQ·10/03 01:15

  IN8bio Consensus Price Target Raised 12% to $7.14

• TipRanks·10/01 14:25

  H.C. Wainwright Remains a Buy on IN8bio (INAB)

• TipRanks·09/22 10:00

  Analysts’ Top Healthcare Picks: IN8bio (INAB), Daré Bioscience (DARE)

• Dow Jones·09/09 12:00

  Press Release: IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

• TipRanks·08/12 01:55

  Mizuho Securities Reaffirms Their Buy Rating on IN8bio (INAB)

• TipRanks·08/07 15:00

  Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Lineage Therap (LCTX) and BioLife Solutions (BLFS)

• Seeking Alpha·08/07 13:51

  IN8bio Non-GAAP EPS of -$0.25

• TipRanks·08/07 10:45

  IN8bio Buy Rating Reiterated as Pipeline Advances and Regulatory Outlook Strengthen; $6 Price Target Maintained

• Dow Jones·08/06 20:01

  Press Release: IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

• TipRanks·07/09 13:35

  IN8bio therapy doubles progression free survival in brain cancer trial

• TipRanks·07/06 07:30

  Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), IN8bio (INAB)

• TipRanks·06/04 10:50

  Analysts Conflicted on These Healthcare Names: Tenaya Therapeutics (TNYA), IN8bio (INAB) and Veeva Systems (VEEV)

• TipRanks·06/01 15:10

  Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), IN8bio (INAB) and PolyPid (PYPD)